Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the
development of revolutionary bone graft material and coatings for
medical applications, today announced that Daniel "Dan" Goldberger has
agreed to become the company’s new Chief Executive Officer. Dan is
expected to start next week.
Dan, has more than 25 years of experience in the medical technology and
device industry. He was most recently CEO of Sound Surgical Technologies
from April 2007 through its merger with Solta Medical (Nasdaq SLTM) in
February 2013. During his career, he has held several executive
leadership positions within the medical device industry, as the CEO and
Director and Xcorporeal Inc. and President of Medical Group of OSI
Systems.
Kent Swanson, Chairman of the Board said: “We are very excited and it is
a great pleasure for us to welcome Dan Goldberger to Bacterin
International. As the Company’s CEO , he will be responsible for
delivering sustainable top-line growth, and achieving profitability. His
deep knowledge of the industry as well as his extensive experience in
sales and marketing and operations as well as financial transformations
will be pivotal in helping the company achieve its strategic objectives,
while meeting customer needs.”
Dan Goldberger commented: “Bacterin International is a formidable
competitor in this burgeoning biologics and regenerative medicine space
with an immense array of products and manufacturing capabilities. I am
impressed with the foundation of business for which I have been given
the responsibility to lead. I look forward to working with the company’s
employees and customers, and driving the business into sustained
profitability for its customers, employees and shareholders.”
Dan is a named inventor on more than 60 US patents. He holds a BS in
Mechanical Engineering from the Massachusetts Institute of Technology
and an MS in Mechanical Engineering from Stanford University.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops,
manufactures and markets biologics products to domestic and
international markets. Bacterin's proprietary methods optimize the
growth factors in human allografts to create the ideal stem cell
scaffold to promote bone, subchondral repair and dermal growth. These
products are used in a variety of applications including enhancing
fusion in spine surgery, relief of back pain, promotion of bone growth
in foot and ankle surgery, promotion of cranial healing following
neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops and licenses coatings for
various medical device applications. For further information, please
visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to significant risks and
uncertainties. Forward-looking statements include statements that are
predictive in nature, that depend upon or refer to future events or
conditions, or that include words such as "continue," "efforts,"
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
"projects," "forecasts," "strategy," "will," "goal," "target,"
"prospects," "potential," "optimistic," "confident," "likely,"
"probable" or similar expressions or the negative thereof. Statements of
historical fact also may be deemed to be forward-looking statements. We
caution that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a
variety of important factors, including, among others the risk factors
listed in the Company's Annual Report on Form 10-K and Quarterly Report
on Form 10-Q under the heading "Risk Factors." The Company undertakes no
obligation to release publicly any revisions to any forward-looking
statements to reflect events or circumstances after the date hereof or
to reflect the occurrence of unanticipated events, except as required by
law.
Copyright Business Wire 2013